NYSE · Healthcare
JOHNSON & JOHNSON (JNJ)
As-reported financials and recent SEC filings for JOHNSON & JOHNSON, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$94.19B
Net income
$26.80B
Net margin
28.5%
Diluted EPS
$11.03
ROE
32.9%
P/E (TTM)
27.9×
Market cap
$579.83B
Debt / equity
0.5×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $94.19B | $88.82B | $85.16B | $79.99B | $78.74B |
| Gross profit | $63.94B | $61.35B | $58.61B | $55.39B | $55.34B |
| Operating income | — | — | — | — | — |
| Net income | $26.80B | $14.07B | $35.15B | $17.94B | $20.88B |
| Diluted EPS | $11.03 | $5.79 | $13.72 | $6.73 | $7.81 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-12
View on EDGAR →1442026-06-11
View on EDGAR →42026-06-11
View on EDGAR →42026-06-11
View on EDGAR →42026-06-11
View on EDGAR →SD2026-05-27
View on EDGAR →13F-HR2026-05-13
View on EDGAR →42026-05-04
View on EDGAR →Go deeper on JNJ
Search JOHNSON & JOHNSON’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.